Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 1,301–1,400 of 10,906
N1-methylpseudouridine found within COVID-19 mRNA vaccines produces faithful protein products
Kim, K. Q., Burgute, B. D., Tzeng, S., Jing, C., Jungers, C. F., Zhang, J., Yan, L. L., Vierstra, R. D., Djuranović, S., Evans, B. S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111300 · Cited by 73
Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa
Reddy, K. P., Fitzmaurice, K. P., Scott, J. A., Harling, G., Lessells, R. J., Panella, C., Shebl, F. M., Freedberg, K. A., & Siedner, M. J. (2021) · Nature Communications · doi:10.1038/s41467-021-26557-5 · Cited by 66
Marra, A. R., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Tofaneto, B. M., Bariani, L. M., Auler, M. D. A., Salinas, J. L., Edmond, M. B., Doll, M. E., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2021.12.035 · Cited by 65
Li, Z., Zhang, X., Ho, W., Bai, X., Jaijyan, D. K., Li, F., Kumar, R., Kolloli, A., Subbian, S., Zhu, H., et al. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204462 · Cited by 67
(2021) · doi:10.1101/2021.10.26.21265397 · Cited by 153
Bonelli, M. M., Mrak, D., Tobudic, S., Sieghart, D., Koblischke, M., Mandl, P., Kornek, B., Simader, E., Radner, H., Perkmann, T., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221558 · Cited by 64
Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine
Kramer, K. J., Wilfong, E. M., Voss, K., Barone, S. M., Shiakolas, A. R., Raju, N., Roe, C. E., Suryadevara, N., Walker, L. M., Wall, S. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31142-5 · Cited by 61
Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry
Kastenhuber, E. R., Mercadante, M., Nilsson-Payant, B. E., Johnson, J. L., Jaimes, J. A., Muecksch, F., Weisblum, Y., Bram, Y., Chandar, V., Whittaker, G. R., et al. (2022) · eLife · doi:10.7554/elife.77444 · Cited by 66
Vaccination in Chronic Liver Disease: An Update
Alukal, J. J., Naqvi, H. A., & Thuluvath, P. J. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.12.003 · Cited by 71
Antigenic characterization of influenza and SARS-CoV-2 viruses
Wang, Y., Tang, C. Y., & Wan, X. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03806-6 · Cited by 73
Chow, K. W., Pham, N. V., Ibrahim, B. M., Hong, K. N., & Saab, S. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07504-w · Cited by 63
RNA modification in mRNA cancer vaccines
Mei, Y., & Wang, X. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01020-5 · Cited by 62
Funk, C. D., Laferrière, C. A., & Ardakani, A. (2021) · Viruses · doi:10.3390/v13030418 · Cited by 61
Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study
Shasha, D., Bareket, R., Sikron, F. H., Gertel, O., Tsamir, J., Dvir, D., Mossinson, D., Heymann, A. D., & Zacay, G. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.018 · Cited by 60
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 68
Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses
Burrows, A., Bartholomew, T., Rudd, J., & Walker, D. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243829 · Cited by 60
Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge
Baden, L. R., El Sahly, H. M., Essink, B., Follmann, D., Neuzil, K. M., August, A., Clouting, H., Fortier, G., Deng, W., Han, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2115597 · Cited by 58
Self-citationSARS‐CoV‐2 and its variants of concern including Omicron: A never ending pandemic
Mohapatra, R. K., Kuppili, S., Suvvari, T. K., Kandi, V., Behera, A., Verma, S., Kudrat‐E‐Zahan, Biswal, S. K., AL-Noor, T. H., El‐ajaily, M. M., et al. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14035 · Cited by 64
Moore, J. P. (2021) · JAMA · doi:10.1001/jama.2021.3465 · Cited by 60
Alhassan, R. K., Owusu‐Agyei, S., Ansah, E., & Gyapong, M. (2021) · Human Resources for Health · doi:10.1186/s12960-021-00657-1 · Cited by 61
The quest for nanoparticle-powered vaccines in cancer immunotherapy
Sun, Z., Zhao, H., Ma, L., Shi, Y., Ji, M., Sun, X., Ma, D., Zhou, W., Huang, T., & Zhang, D. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02311-z · Cited by 72
Martins‐Filho, P. R., Ferreira, L. C., Heimfarth, L., Araújo, A. A. D. S., & Quintans‐Júnior, L. J. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100062 · Cited by 68
Brasu, N., Elia, I., Russo, V., Montacchiesi, G., Stabile, S. A., Intinis, C. D., Fesi, F., Gizzi, K., Macagno, M., Montone, M., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01313-z · Cited by 62
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months
Hsu, C. M., Weiner, D. E., Manley, H. J., Aweh, G. N., Ladik, V., Frament, J., Miskulin, D., Agyropoulos, C., Abreo, K. D., Chin, A., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12250921 · Cited by 61
Fraley, E., LeMaster, C., Geanes, E. S., Banerjee, D., Khanal, S., Grundberg, E., Selvarangan, R., & Bradley, T. (2021) · BMC Medicine · doi:10.1186/s12916-021-02055-9 · Cited by 65
Li, X., Burn, E., Duarte‐Salles, T., Yin, C., Reich, C., Delmestri, A., Verhamme, K. M. C., Rijnbeek, P. R., Suchard, M. A., Li, K., et al. (2022) · BMJ · doi:10.1136/bmj-2022-071594 · Cited by 67
Durability of immune responses to the BNT162b2 mRNA vaccine
Suthar, M. S., Arunachalam, P. S., Hu, M., Reis, N., Trisal, M., Raeber, O., Chinthrajah, R. S., Davis-Gardner, M. E., Manning, K. E., Mudvari, P., et al. (2022) · Med · doi:10.1016/j.medj.2021.12.005 · Cited by 66
VILCHES, T. N., Nourbakhsh, S., Zhang, K., Juden-Kelly, L., Cipriano, L. E., Langley, J. M., Sah, P., Galvani, A. P., & Moghadas, S. M. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106564 · Cited by 68
Nanomaterials‐Mediated Co‐Stimulation of Toll‐Like Receptors and CD40 for Antitumor Immunity
Yan, J., Zhang, Y., Du, S., Hou, X., Li, W., Zeng, C., Zhang, C., Cheng, J. K. J., Deng, B., McComb, D. W., et al. (2022) · Advanced Materials · doi:10.1002/adma.202207486 · Cited by 63
Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines
Mouro, V., & Fischer, A. (2022) · Mucosal Immunology · doi:10.1038/s41385-022-00517-8 · Cited by 61
Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection
Yilmaz, I. C., İpekoğlu, E. M., Bulbul, A., Turay, N., Yıldırım, M., Evcili, İ., Yilmaz, N. S., Guvencli, N., Aydin, Y., Gungor, B., et al. (2021) · Allergy · doi:10.1111/all.15091 · Cited by 66
Universal Barcoding Predicts In Vivo ApoE-Independent Lipid Nanoparticle Delivery
Sanchez, A. J. D. S., Dobrowolski, C. N., Cristian, A., Echeverri, E. S., Zhao, K., Hatit, M. Z. C., Loughrey, D., Paunovska, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01133 · Cited by 66
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
(2022) · doi:10.1101/2022.08.07.499047 · Cited by 59
Nachtigall, I., Bonsignore, M., Hohenstein, S., Bollmann, A., Günther, R., Kodde, C., Englisch, M., Ahmad‐Nejad, P., Schröder, A., Glenz, C., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07284-8 · Cited by 62
Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans
Young-Xu, Y., Korves, C., Roberts, J., Powell, E. I., Zwain, G. M., Smith, J., & Izurieta, H. S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.28391 · Cited by 58
Goel, R. R., Painter, M. M., Apostolidis, S. A., Mathew, D., Meng, W., Rosenfeld, A. M., Lundgreen, K. A., Reynaldi, A., Khoury, D. S., Pattekar, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.23.457229 · Cited by 59
Reasons for success and lessons learnt from nanoscale vaccines against COVID-19
Kisby, T., Yılmazer, A., & Kostarelos, K. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00946-9 · Cited by 68
Wang, Y., Yang, K., & Zhou, H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.125515 · Cited by 61
Self-citationProphylactic HIV-1 vaccine trials: past, present, and future
Nkolola, J. P., & Barouch, D. H. (2023) · The Lancet HIV · doi:10.1016/s2352-3018(23)00264-3 · Cited by 72
Netti, G. S., Infante, B., Troise, D. E., Mercuri, S., Panico, M., Spadaccino, F., Catalano, V., Gigante, M., Simone, S., Pontrelli, P., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.16958 · Cited by 67
Poukka, E., Baum, U., Palmu, A. A., Lehtonen, T. O., Salo, H., Nohynek, H., & Leino, T. (2022) · Vaccine · doi:10.1016/j.vaccine.2021.12.032 · Cited by 58
Kerr, S., Joy, M., Torabi, F., Bedston, S., Akbari, A., Agrawal, U., Beggs, J., Bradley, D., Chuter, A., Docherty, A. B., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1003927 · Cited by 62
Machine Learning‐Enhanced Nanoparticle Design for Precision Cancer Drug Delivery
Wang, Q., Liu, Y., Li, C., Xu, S., Xu, S., & Liu, B. (2025) · Advanced Science · doi:10.1002/advs.202503138 · Cited by 103
Buske, C., Dreyling, M. H., Álvarez‐Larrán, A., Apperley, J. F., Arcaini, L., Besson, C., Bullinger, L., Corradini, P., Porta, M. G. D., Dimopoulos, M. A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100403 · Cited by 66
IgA Nephropathy After SARS-CoV-2 Vaccination
Abramson, M. H., Yu, S. M.-W., Campbell, K. N., Chung, M., & Salem, F. E. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.05.002 · Cited by 61
Wagner, A., Garner‐Spitzer, E., Schötta, A., Orola, M. J., Wessely, A., Zwazl, I., Ohradanova‐Repic, A., Weseslindtner, L., Tajti, G., Gebetsberger, L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889138 · Cited by 61
Goletti, D., Petrone, L., Manissero, D., Bertoletti, A., Rao, S. N., Ndunda, N., Sette, A., & Nikolayevskyy, V. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.005 · Cited by 78
Zhou, W., Jiang, L., Liao, S., Wu, F., Yang, G., Hou, L., Liu, L., Pan, X., Jia, W. W.-G., & Zhang, Y. (2023) · Viruses · doi:10.3390/v15081760 · Cited by 70
Hertel, M., Heiland, M., Nahles, S., von Laffert, M., Mura, C., Bourne, P. E., Preißner, R., & Preißner, S. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18184 · Cited by 68
Selma‐Royo, M., Bäuerl, C., Tudela, D. M., Aguilar‐Camprubí, L., Pérez-Cano, F. J., Llorca, A. P., Lerín, C., Martínez‐Costa, C., & Collado, M. C. (2022) · Genome Medicine · doi:10.1186/s13073-022-01043-9 · Cited by 67
Canaday, D. H., Oyebanji, O. A., White, E. M., Keresztesy, D., Payne, M., Wilk, D. J., Carias, L. L., Aung, H., Denis, K. S., Sheehan, M. L., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104066 · Cited by 61
Current progress in the development of prophylactic and therapeutic vaccines
Li, T., Qian, C., Gu, Y., Zhang, J., Li, S., & Xia, N. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2230-4 · Cited by 63
Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland
Shattock, A. J., Rutte, E. A. L., Dünner, R. P., Sen, S., Kelly, S. L., Chitnis, N., & Penny, M. A. (2021) · Epidemics · doi:10.1016/j.epidem.2021.100535 · Cited by 69
Principles of lipid nanoparticle design for mRNA delivery
Zhang, Y., Zhang, X., Gao, Y., & Liu, S. (2024) · BMEMat · doi:10.1002/bmm2.12116 · Cited by 71
Yeast as carrier for drug delivery and vaccine construction
Tan, Y., Chen, L., Li, K., Lou, B., Liu, Y., & Liu, Z. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.032 · Cited by 67
Feldman, J. E., Bals, J., Altomare, C. G., Denis, K. S., Lam, E. C., Hauser, B. M., Ronsard, L., Sangesland, M., Moreno, T. B., Okonkwo, V., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5842 · Cited by 61
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
Corbett, K. S., Werner, A. P., Connell, S. O., Gagne, M., Lai, L., Moliva, J. I., Flynn, B., Choi, A., Koch, M., Foulds, K. E., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01021-0 · Cited by 57
Self-citationThe mRNA-LNP vaccines – the good, the bad and the ugly?
Igyártó, B. Z., & Qin, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336906 · Cited by 71
Bradley, B. T., Bryan, A. B., Fink, S. L., Goecker, E. A., Roychoudhury, P., Huang, M.-L. W., Zhu, H., Chaudhary, A., Madarampalli, B., Lu, J., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00989-21 · Cited by 56
Monoclonal antibody levels and protection from COVID-19
Stadler, E., Burgess, M. T., Schlub, T. E., Khan, S. R., Chai, K. L., McQuilten, Z., Wood, E. M., Polizzotto, M. N., Kent, S. J., Cromer, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40204-1 · Cited by 65
Karunakaran, B., Gupta, R., Patel, P., Salave, S., Sharma, A. K., Desai, D. N., Benival, D. M., & Kommineni, N. (2023) · Vaccines · doi:10.3390/vaccines11030661 · Cited by 70
Enabling mRNA Therapeutics: Current Landscape and Challenges in Manufacturing
Youssef, M., Hitti, C., Fulber, J. P. C., & Kamen, A. (2023) · Biomolecules · doi:10.3390/biom13101497 · Cited by 72
Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency
Arroyo‐Sánchez, D., Cabrera-Marante, Ó., Laguna‐Goya, R., Almendro-Vázquez, P., Carretero, O., Gil‐Etayo, F. J., Suàrez-Fernández, P., Pérez‐Romero, P., de Frías, E. R., Serrano, A., et al. (2021) · Journal of Clinical Immunology · doi:10.1007/s10875-021-01174-5 · Cited by 64
Targeting nucleic acid-based therapeutics to tumors: Challenges and strategies for polyplexes
Vetter, V. C., & Wagner, E. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.013 · Cited by 65
Tamari, R., Politikos, I., Knorr, D. A., Vardhana, S. A., Young, J. C., Marcello, L. T., Doddi, S., Devlin, S. M., Ramanathan, L. V., Pessin, M. S., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0142 · Cited by 55
Sridhar, S., Joaquin, A., Bonaparte, M. I., Bueso, A., Chabanon, A.-L., Chen, A., Chicz, R. M., Diemert, D. J., Essink, B. J., Fu, B., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00764-7 · Cited by 62
Self-citationBahnan, W., Wrighton, S., Sundwall, M., Bläckberg, A., Larsson, O. J., Höglund, U., Khakzad, H., Godzwon, M., Walle, M., Elder, E. E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.808932 · Cited by 62
Du, S., Li, W., Zhang, Y., Xue, Y., Hou, X., Yan, J., Cheng, J. K. J., Deng, B., McComb, D. W., Lin, J. S., et al. (2023) · Advanced Science · doi:10.1002/advs.202300188 · Cited by 66
Parvin, N., Joo, S. W., & Mandal, T. K. (2024) · Biomolecules · doi:10.3390/biom14081036 · Cited by 77
33 Unresolved Questions in Nanoscience and Nanotechnology
Mirkin, C. A., Petrosko, S. H., Artzi, N., Aydın, K., Biaggne, A., Brinker, C. J., Bujold, K. E., Cao, Y. C., Chan, R. R., Chen, C., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c12854 · Cited by 69
A chitosan-mediated inhalable nanovaccine against SARS-CoV-2
Zhuo, S., Wu, J., Zhao, L., Li, W., Zhao, Y., & Li, Y. (2022) · Nano Research · doi:10.1007/s12274-021-4012-9 · Cited by 58
Structural Basis for SARS-CoV-2 Nucleocapsid Protein Recognition by Single-Domain Antibodies
Ye, Q., Lu, S., & Corbett, K. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.719037 · Cited by 57
Efficacy of COVID-19 vaccines: From clinical trials to real life
Deplanque, D., & Launay, O. (2021) · Therapies · doi:10.1016/j.therap.2021.05.004 · Cited by 63
Adverse Reactions of COVID-19 Vaccines: A Scoping Review of Observational Studies
Dhamanti, I., Suwantika, A. A., Adlia, A., Yamani, L. N., & Yakub, F. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s400458 · Cited by 62
Hesitancy towards COVID-19 Vaccines: An Analytical Cross–Sectional Study
Aloweidi, A. S., Bsisu, I., Suleiman, A., Abu‐Halaweh, S. A., Mustafa, M., Aqel, M., Amro, A., Radwan, N., Assaf, D. H., Abdullah, M. Z., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18105111 · Cited by 62
Durability of Heterologous and Homologous COVID-19 Vaccine Boosts
Tan, C. S., Collier, A.-R. Y., Yu, J., Liu, J., Chandrashekar, A., McMahan, K., Jacob-Dolan, C., He, X., Roy, V., Hauser, B. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.26335 · Cited by 61
Hosani, F. I. A., Stanciole, A. E., Aden, B., Timoshkin, A., Najim, O., Zaher, W. A., AlDhaheri, F. A., Mazrouie, S. A., Rizvi, T. A., & Mustafa, F. (2021) · Vaccine · doi:10.1016/j.vaccine.2022.02.039 · Cited by 64
SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study
Shields, A. M., Faustini, S. E., Hill, H. J., Al‐Taei, S., Tanner, C., Ashford, F. B., Workman, S., Moreira, F., Verma, N., Wagg, H., et al. (2022) · Journal of Clinical Immunology · doi:10.1007/s10875-022-01231-7 · Cited by 66
Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors
Waldhorn, I., Holland, R., Goshen‐Lago, T., Shirman, Y., Szwarcwort‐Cohen, M., Benaim, A. R., Shachor‐Meyouhas, Y., Hussein, K., Fahoum, L., Peer, A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1072 · Cited by 63
Shapiro, J. R., Sitaras, I., Park, H. S., Aytenfisu, T. Y., Caputo, C. A., Li, M., Lee, J., Johnston, T. S., Li, H., Wouters, C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac397 · Cited by 58
Acute encephalitis, myoclonus and Sweet syndrome after mRNA-1273 vaccine
Acosta, G. T., Martin, J., Huttenbach, Y., García, C. R., Sohail, M. R., Agarwal, S. K., Wasko, C. A., Bershad, E. M., & Hirzallah, M. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243173 · Cited by 59
Clinical development of therapeutic mRNA applications
Żak, M. M., & Zangi, L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.034 · Cited by 79
Age-related heterogeneity in immune responses to SARS-CoV-2 vaccine BNT162b2
(2021) · doi:10.1101/2021.02.03.21251054 · Cited by 750
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57
Thomas, S. J., Perez, J. L., Lockhart, S. P., Hariharan, S., Kitchin, N. R. E., Bailey, R. E., Liau, K., Lagkadinou, E., Türeci, Ö., Şahin, U., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.12.046 · Cited by 67
Development and applications of mRNA treatment based on lipid nanoparticles
Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 59
Kant, A. C., Jansen, J. R. G., van Balveren, L., & van Hunsel, F. P. A. M. (2022) · Drug Safety · doi:10.1007/s40264-022-01151-w · Cited by 59
Tailoring the physicochemical properties of nanomaterials for immunomodulation
Deng, J., Wang, J., Shi, J., Li, H., Lu, M., Fan, Z., Gu, Z., & Cheng, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114039 · Cited by 64
Could live attenuated vaccines better control COVID-19?
Okamura, S., & Ebina, H. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.018 · Cited by 70
COVID-19: Insights into Potential Vaccines
Loo, K.-Y., Letchumanan, V., Ser, H., Teoh, S. L., Law, J. W., Tan, L. T., Mutalib, N. A., Chan, K., & Lee, L. (2021) · Microorganisms · doi:10.3390/microorganisms9030605 · Cited by 62
Ishii, H., Nomura, T., Yamamoto, H., Nishizawa, M., Hau, T. T. T., Harada, S., Seki, S., Nakamura‐Hoshi, M., Okazaki, M., Daigen, S., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100520 · Cited by 63
Padoan, A., Bonfante, F., Cosma, C., Chiara, C. D., Sciacovelli, L., Pagliari, M., Bortolami, A., Costenaro, P., Musso, G., Basso, D., et al. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0313 · Cited by 57
Deep learning models for predicting RNA degradation via dual crowdsourcing
Wayment-Steele, H. K., Kladwang, W., Watkins, A. M., Kim, D. S., Tunguz, B., Reade, W., Demkin, M., Romano, J., Wellington-Oguri, R., Nicol, J. J., et al. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00571-8 · Cited by 76
Rosano, G. M. C., Jankowska, E. A., Ray, R., Metra, M., Abdelhamid, M., Adamopoulos, S. N., Anker, S. D., Bayés‐Genís, A., Belenkov, Y. N., Gal, T. B., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2356 · Cited by 64
Economic evaluation for mass vaccination against COVID-19
Wang, W., Fann, J. C., Chang, R., Jeng, Y., Hsu, C.-Y., Chen, H.-H., Liu, J., & Yen, A. M. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.05.020 · Cited by 59
Vaccination Prioritization Strategies for COVID-19 in Korea: A Mathematical Modeling Approach
Choi, Y., Kim, J. S., Kim, J. E., Choi, H., & Lee, C. H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18084240 · Cited by 64
Søgaard, O. S., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Stærke, N. B., Iversen, K. K., Fogh, K., Bodilsen, J., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.03.003 · Cited by 62
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.